Symptomatic myopathy during interferon alfa therapy for chronic myelogenous leukemia.
A
A
Falcone
C A
CA
Bodenizza
P
P
Musto
M
M
Carotenuto
D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D003402:Creatine Kinase / Q000378:metabolism; D006801:Humans; D007370:Interferon Type I / Q000009:adverse effects* / Q000627:therapeutic use; D007527:Isoenzymes; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000150:complications* / Q000188:drug therapy; D008297:Male; D017285:Polymyositis / Q000139:chemically induced* / Q000201:enzymology / Q000209:etiology; D011994:Recombinant Proteins
D000970:Antineoplastic Agents; D007370:Interferon Type I; D007527:Isoenzymes; D011994:Recombinant Proteins; D003402:Creatine Kinase